Sign in to view content

APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies

Michael J Allingham, MD, PhD

Video
Published 2021

Related

Clinical Effects of Blocking Ang-2 and VEGF with Faricimab in the Phase 2 STAIRWAY Trial
Carl J Danzig, MD
Annual Meeting Talks
2020
Treatment Patterns and Vision Changes in Anti-VEGF Refractory Diabetic Macular Edema After Dexamethasone Implant in US Clinical Practice
Yasha S Modi, MD
On Demand Cases, Courses, and Papers
2021
Elamipretide, a Mitochondria-Targeted Drug for the Treatment of Vision Loss
Scott W. Cousins, MD
Updates from the Field
2019

Category: Diabetic Retinopathy

See more